KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $226.5 million.

  • Acadia Pharmaceuticals' Net Income towards Common Stockholders rose 119.07% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.2 million, marking a year-over-year increase of 103.24%. This contributed to the annual value of $226.5 million for FY2024, which is 469.50% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Net Income towards Common Stockholders of $226.5 million as of FY2024, which was up 469.50% from -$61.3 million recorded in FY2023.
  • Acadia Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $226.5 million for FY2024, and its period low was -$281.6 million during FY2020.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$61.3 million (2023), whereas its average is -$16.9 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first decreased by 28.66% in 2022, then surged by 469.50% in 2024.
  • Acadia Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at -$281.6 million in 2020, then soared by 40.38% to -$167.9 million in 2021, then declined by 28.66% to -$216.0 million in 2022, then spiked by 71.62% to -$61.3 million in 2023, then soared by 469.50% to $226.5 million in 2024.